bluuebunny/crossref_metadata_2025_split huggingface dataset:
Specific IgE and skin tests to house dust and storage mites and eosinophil cationic protein in scabies
Authors: Haustein U.‐F. , Maus C. , Zschiesche A. , Münzberger Chr. 
Published: August 2010

AbstractBackground In addition to the infestation with scabies mites also allergic IgE mediated mechanisms play a role in the pathogenesis of scabies.Aim The aim of this study was to answer the question whether specific IgE mediated reactions to house dust and storage mites can be found and whether eosinophils are involved in the pathogenesis of scabies.Material 44 scabies patients (12 children. 32 adults) were classified according to the extent of skin involvement as mild, moderate and severe. Age‐ and sex‐matched healthy controls and patients with atopic dermatitis were studied for comparative purposes.Methods Total and specific IgE to Dermatophagoides pteronyssinus, D. farinae, Acartis siro and Pityrosporon ovale were tested by CAP‐FEIA (Pharmacia. Sweden) before and 6 weeks after treatment and prick tests were performed with the same allergens. The number of eosinophils in the peripheral blood and tissue specimens was counted and the eosinophil cationic protein (ECP) was determined by CAP‐FEIA in serum before and 6 weeks after therapy.Results The total IgE was increased in 86% of patients. It was correlated with the extent of skin involvement (p < 0.05) and was significantly less increased 6 weeks after treatment (p < 0.115). Specific IgE to house dust and storage mites was increased up to 48% in the CAP‐EEIA and up to 61% in the prick test, all together significantly higher than in controls and in comparable frequencies with atopic dermatitis. Pityrosporon ovate IgE was within normal ranges. Die ECP levels were increased in 89% of patients and correlated only in mild versus moderate or severe extent of the disease. 6 weeks after treatment, however, they were significantly less increased (p < 1.01). In addition. ECP levels were correlated with the IgE levels in scabies (C = 0.88). The number of eosinophils in the peripheral blood was increased in 64% of cases and in tissue specimens in 84% of cases studied. In principle, the extent of skin lesions was milder and the frequencies of specific IgE in the CAP‐ and prick test as well as the levels of total IgE (p < 0.01) and ECP (only in the tendency) were lower in children than in adults.Discussion The frequencies in the total and specific IgE to house dust and storage mites are comparable with those in atopic dermatitis. The question remains open, whether this is due to cross reactivity with scabies mites or whether this suggests an enhanced susceptibility to generalized scabies eruption. The increase in the ECP and its correlation to IgE, its decline after treatment (p < 0.05) and the occurrence of eosinophils in the peripheral blood and in inflammatory infiltrates of the skin suggest the involvement of eosinophils in the pathogenesis of scabies as an ectoparasitic IgE mediated disease.
A symmetrical pustular auricular eruption due to recurrent HSV infection
Authors: Papadavid E. , Munn S. , Chu A.C. 
Published: August 2010

AbstractWe report a patient with a symmetrical presentation of HSV infection on both pinna, recurrent since his childhood. Our patient used to play rugby as a student and we feel that the symmetrical and unusual distribution for his viral infection may be related to direct inoculation due to trauma sustained in contact sports and subsequent autoinoculation. To our knowledge, no similar symmetrical presentation of HSV infection has been reported in the literature.
Hypereosinophilic syndrome as prodrome of bullous pemphigoid:report of a case
Authors: Palleschi G. M. , Caproni M. , Falcos D. , Giacomelli A. , Fabbri P. 
Published: August 2010

AbstractPersistent hypereosinophilia, cardiac involvement and a recurrent erythematous‐papular pruritic eruption histologically characterized by eosinophilic spongiosis are described in a 77‐year‐old man. This condition, suggestive of “idiopathic” hypereosinophilic syndrome, represented the prodromic phase of atypical bullous pemphigoid, which manifested 7 months later.
Cutaneous manifestations in an autistic population
Authors: Srebrnik Avigdor , Brenner Sarah , Holan Agatha , Stein Daniel , Elizur Avner 
Published: August 2010

AbstractBackground The observation of combinations of cutaneous signs that appear to be specific to autistic patients indicates a possible genetic association between autism and certain cutaneous manifestations.Objective To examine the possibility of a genetic association between autism and cutaneous manifestations in an autistic population compared to a control group of psychiatric patients.Subjects and methods Seventy‐four autistic and 67 psychiatric hospitalized patients underwent routine skin examination by it physician who was unaware of the patient individual diagnosis, medical history and family background. Data on concomitant diseases, family medical history, drug therapy and dermatologic findings were compared in the two populations.Results The autistic population had a significantly higher frequency of seborrhea, atypical nevi, pigmentation, baldness and seizures, which may have a genetic background.Conclusions The findings point to the possible genetic nature of autism, a speculation that requires further study.
PURPLE (atrophie blanche): clinical, histological and immunological study of twelve patients
Authors: Papi Massimo , Didona Biagio , De Pità Ornella , Silvestri Lorena , Ferranti Giulio , Gantcheva Mary , Chinni Luca Massimo 
Published: August 2010

AbstractObjectives To investigate clinical, serologic, histopathologic and immunopathologic markers of PURPLE (painful purpuric ulcers with reticular pattern of lower extremities) or atrophie blanche.Design Twelve consecutive patients affected with idiopathic PURPLE were studied in the period 1992–1996. Patients with systemic diseases correlated to PURPLE were excluded from the study.Subjects All twelve patients were hospitalized at the Istituto Dermopatico Immacolata in Rome.Results Various and dishomogeneous immunological alterations were detected. Circulating immune complexes, increased serum levels of anticardiolipin and antinuclear antibodies, reduced serum complement levels, and deposition of immunoreactants in dermal vessels, were found in a limited number of patients. The results were not statistically significant. All the patients showed very similar histopathological aspects, characterized by microvascular thromboses, endothelial swelling and segmental hyalinization of small dermal vessels.Conclusion PURPLE is a thrombogenic vasculopathy in which unspecified immunological and laboratory changes are present. The recently suggested pathogenetic role of anticardiolipin and protein C deficiency in the disorder is not confirmed by this study.
Non‐bullous, erythema annulare‐like pemphigus
Authors: Mastrolonardo Mario , Conte Adele , Rantuccio Franco 
Published: August 2010

AbstractA 25‐year‐old woman presented with a 1‐month duration, mildly pruritic, erythema annulare‐like rash involving the trunk and proximal aspects of the limbs, in the absence of any clinically obvious blister formation. Only discrete scaling and very sparse vesiculation were detected mainly at the periphery of the lesions. Biopsy specimens for histopathologic examination and direct immunofluorescence study showed typical pemphigus findings. Circulating anti‐epidermal cell surface antibodies were also detected with indirect immunofluorescence tests. The erythema annulare‐like pattern of presentation of pemphigus is exceedingly rare; nevertheless, this possibility should be considered in the differential diagnosis of persistent, annular and figurate erythematous eruptions.
Drug‐induced pemphigus. Does a relationship exist between inducing drug and lesion topography?
Authors: Brenner Sarah , Bialy‐Golan Anat , Ophir Joseph , Ruocco Vincenzo 
Published: August 2010

AbstractPemphigus subclasses differ both in target epidermal antigen of the autoantibodies and in predilection sites of lesions. The patterns of lesions are well documented and often lead to diagnosis of the subtype of the disease: but the causative factors have never been studied. We present a case of pemphigus exacerbated by two unrelated drugs, with distinct exacerbation‐specific patterns following each drug consumption. The patient is regarded as exemplifying a fixed drug eruption‐like phenomenon, with specificity of drug to anatomic distribution of lesions.
Erythrodermic bullous pemphigoid
Authors: Grunwald Marcelo H. , Amichai Boaz , Giryes Hani , Halevy Sima 
Published: August 2010

AbstractWe report a case of erythrodermic type of bullous pemphigoid which is a rare variant of bullous pemphigoid. Our patient had a peculiar clinical presentation with bullae, erosions and extensive erythrodermic areas, and distinct direct immunofluorescent findings which included linear IgG and C3 deposits in the basement membrane and also IgG in the intercellular spaces. Very high levels of serum IgE were also detected in our patient.
ANZSJA's Songlines and Haerenga model of training
Authors: Caulfield Margaret , Norton Joy 
Published: August 2010

Abstract:  Part One and Part Two of this article present the Australian and New Zealand Society of Jungian Analysts' 2006 model of training. The authors describe the process and thinking behind ANZSJA's recent revision of training.The influences on the development of analytical psychology and analytic training in ANZSJA are traced in the first paper. The training review undertaken indicated the desire for ANZSJA to continue to train Jungian analysts by exploring new ways of conceptualizing training. The images, metaphors and thinking, which underlie this innovative training model, are explored. The challenge involved in providing and developing training across a large geographic region with widely distributed and slender resources was embraced. ANZSJA have acknowledged the traditional practices of Australian and New Zealand indigenous peoples. The motif of journey and movement is at the core of the ANZJSA model. The ANZJSA training is not held or contained in a building or buildings but rather held at ‘meeting sites’ across the landscape of these two countries.Accountability and transparency are central to this training model. In Part Two of the article the structure and documentation developed for this model are contextualized, outlined and linked to the ethos underpinning the current thrust of analytical training in Australia and New Zealand. The focus is the practical mechanisms and processes, which we have evolved to deliver our new training model. The process of engaging analysts in the new model is discussed.
The influence of a fast ramp rate on peak cardiopulmonary parameters during arm crank ergometry
Authors: Castro Renata R. T. , Pedrosa Sabrina , Chabalgoity Fernanda , Sousa Eduardo B. , Nobrega Antonio C. L. 
Published: August 2010

SummaryThe influence of a very fast ramp rate on cardiopulmonary variables at ventilatory threshold and peak exercise during a maximal arm crank exercise test has not been extensively studied. Considering that short arm crank tests could be sufficient to achieve maximal oxygen consumption (VO2), it would be of practical interest to explore this possibility. Thus, this study aimed to analyse the influence of a fast ramp rate (20 W min−1) on the cardiopulmonary responses of healthy individuals during a maximal arm crank ergometry test. Seventeen healthy individuals performed maximal cardiopulmonary exercise tests (Ultima CardiO2; Medical Graphics Corporation, St Louis, USA) in arm ergometer (Angio, LODE, Groningen, The Netherlands) following two protocols in random order: fast protocol (increment: 2 w/6 s) and slow protocol (increment: 1 w/6 s). The fast protocol was repeated 60–90 days after the 1st test to evaluate protocol reproducibility. Both protocols elicited the same peak VO2 (fast: 23·51 ± 6·00 versus slow: 23·28 ± 7·77 ml kg−1 min−1; P = 0·12) but peak power load in the fast ramp protocol was higher than the one in the slow ramp protocol (119 ± 43 versus. 102 ± 39 W, P < 0·001). There was no other difference in ventilatory threshold and peak exercise variables when 1st and 2nd fast protocols were compared. Fast protocol seems to be useful when healthy young individuals perform arm cardiopulmonary exercise test. The usefulness of this protocol in other populations remains to be evaluated.
Peak cardiac power output in healthy, trained men
Authors: Schlader Zachary J. , Mündel Toby , Barnes Matthew J. , Hodges Lynette D. 
Published: August 2010

SummaryPrevious investigations into peak cardiac power output (CPO peak) have been limited to clinical populations and healthy, but non‐athletic adults, and normative data on trained individuals would allow a greater understanding of this parameter. Therefore, we recruited eight healthy, well‐trained male cyclists. Peak oxygen consumption ( peak) was assessed using an incremental ergometer test, and following a 40‐min recovery period, peak cardiac output (T peak) was measured during a constant load test that elicited peak (±5%) using the Defares CO2 rebreathing technique. CPO peak was calculated as described by Cooke et al. (1998). Mean (±SD) values during the constant load test were: peak, 4·94 ± 0·41 l min−1; T peak, 36·5 ± 3·7 l min−1; mean arterial pressure, 123 ± 8 mmHg and CPO peak, 9·9 ± 1·0 W. These results demonstrate CPO peak in a well‐trained population to be approximately twice those observed in healthy, but non‐athletic adults. The current data provide useful information regarding the upper limits and possible ‘trainability’ of cardiac pumping capacity for sedentary and clinically compromised individuals.
AHC‐52, a Dihydropyridine Compound with Chloride Current Blocking and Cardioprotective Activities
Authors: Tanaka Hikaru , Shigenobu Koki 
Published: August 2010

SUMMARYAHC‐52 is a dihydropyridine compound known to reverse multidrug resistance through inhibition of the P‐glycoprotein. In whole‐cell voltage‐clamped cardiomyocytes, AHC‐52 had no effect on L‐type calcium current but inhibited cAMP‐activated chloride current. In an ischemia‐reperfusion model with coronary‐perfused right ventricular tissue, AHC‐52 markedly enhanced the recovery of contractile force on reperfusion without any negative inotropic effect during normal perfusion and experimental ischemia, which is similar to the effects of chloride blockers such as 9‐anthracenecarboxylic acid (9AC) and 4‐acetamido‐4′isothiocyanostilbene‐2,2 disulfonic acid (SITS). Thus, AHC‐52 appears to be an interesting prototype of cardioprotective drugs acting through mechanisms related to modification of anion homeostasis.
A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor Antagonist
Authors: Wienen Wolfgang , Entzeroth Michael , van Meel Jacobus C. A. , Stangier Joachim , Busch Ulrich , Ebner Thomas , Schmid Jochen , Lehmann Horst , Matzek Kandace , Kempthorne‐Rawson Joan , Gladigau Volker , Hauel Norbert H. 
Published: August 2010

ABSTRACTTelmisartan is a potent, long‐lasting, nonpeptide antagonist of the angiotensin II type‐1 (AT1) receptor that is indicated for the treatment of essential hypertension. It selectively and insurmountably inhibits stimulation of the AT1receptor by angiotensin II without affecting other receptor systems involved in cardiovascular regulation. Very high lipophilicity, a unique feature of telmisartan, coupled with a high volume of distribution, indicate that the compound offers the clinically important advantage of good tissue penetration. Telmisartan is not a prodrug and has a longer terminal elimination half‐life than other commercially available sartans (∼24 h), making it suitable for once‐daily dosing. The compound is not metabolized by cytochrome P450 isoenzymes and has a low risk for P450‐based drug interactions. In animal models, telmisartan exhibits pronounced cardio‐and renoprotective effects in animals with severe, essential hypertension. In clinical studies, telmisartan shows comparable antihypertensive activity to members of other major antihypertensive classes, such as ACE inhibitors, beta blockers and calcium antagonists. These trials have confirmed the placebo‐like safety and tolerability of telmisartan in hypertensive patients. Based on these data, telmisartan offers advantages over other sartans and represents an important new treatment option for hypertension.
Multilateral in Vivo and in Vitro Protective Effects of the Novel Heat Shock Protein Coinducer, Bimoclomol: Results of Preclinical Studies
Authors: Nánási P. P. , Jednákovits A. 
Published: August 2010

ABSTRACTBimoclomol, the recently developed non‐toxic heat shock protein (HSP) coinducer, was shown to display multilateral protective activities against various forms of stress or injuries at the level of the cell, tissue or organism. The compound enhanced the transcription, translation and expression of the 70 kD heat shock protein (HSP‐70) in myogenic and HeLa cell lines exposed to heat stress, and increased cell survival on exposure to otherwise lethal thermal injury. Bimoclomol increased contractility of the working mammalian heart, this effect was associated with the increased intracellular calcium transients due to increased probability of opening of ryanodine receptors in the sarcoplasmic reticulum (SR). In healthy tissues these cardiac effects were evident only at relatively high concentrations of the drug, while in the ischemic myocardium bimoclomol exerted significant cardioprotective and antiarrhythmic effects at submicromolar concentrations. It decreased ischemia‐induced reduction of contractility and of cardiac output, and dramatically decreased the elevation of the ST‐segment during ischemia as well as the occurrence of ventricular fibrillation upon reperfusion.Bimoclomol was also active in various pathological animal models subjected to acute or chronic stress. In the spontaneously hypertensive rats chronic pretreatment with bimoclomol restored sensitivity of aortic rings to acetylcholine; this effect was accompanied by accumulation of HSP‐70 in the tissues. Bimoclomol pretreatment significantly diminished the consequences of vascular disorders associated with diabetes mellitus. Diabetic neuropathy, retinopathy, and nephropathy were prevented or diminished, while wound healing was enhanced by bimoclomol. Enhancement of wound healing by bimoclomol was observed after thermal injury as well as following ultraviolet (UV) irradiation. In addition to the beneficial effects on peripheral angiopathies, bimoclomol antagonized the increase in permeability of blood‐brain barrier induced by subarachnoid hemorrhage or arachidonic acid.A general and very important feature of the above effects of bimoclomol was that the drug failed to cause alterations under physiological conditions (except the enhanced calcium release from cardiac sarcoplasmic reticulum). Bimoclomol was effective only under conditions of stress. Consistent with its HSP‐coinducer property, bimoclomol alone had very little effect on HSP production. Its protective activity became apparent only in the presence of cell damage. Currently, bimoclomol reached the end of the Phase II clinical trial in a group of 410 patients with diabetic complications. Results of this trial will answer the question, whether a compound with promising in vitro and in vivo preclinical findings will produce the anticipated beneficial effects in humans. In the event of a positive outcome of this trial, the indications for bimoclomol will be substantially extended.
Pranidipine, a 1,4‐Dihydropyridine Calcium Channel Blocker that Enhances Nitric Oxide‐Induced Vascular Relaxation
Authors: Mori Toyoki , Takase Hiromichi , Toide Kiyotaka , Hirano Takahiro , Kambe Toshimi , Nakayama Natsuki , Schwartz Arnold 
Published: August 2010

ABSTRACTPranidipine, a long acting 1,4‐dihydropyridine calcium channel blocker, prolongs nitric oxide (NO)‐mediated relaxation of rat aorta; it prolongs acetylcholine‐induced relaxation in presence of endothelium as well as nitroglycerin‐induced relaxation in absence of endothelium. In rat aorta the effect of pranidipine on NO‐mediated relaxation is cyclic guanosine monophosphate (cGMP)‐independent, but in guinea pig carotid artery the same effect of pranidipine is cGMP‐dependent. It has been reported that in co‐cultured human endothelial and smooth muscle cells pranidipine, at a higher concentration (10−6M), enhances vasorelaxant effect of NO by blocking NO decomposition. The enhancement of NO action by pranidipine differs from the direct NO‐releasing action of other 1,4‐dihydropyridines. It is expected that enhancement of NO‐induced vasodilatation will lead to a venodilator action in vivo and less peripheral edema. The target organ protective effects of pranidipine are also reviewed in this article.
Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents — The Selective Factor Xa Inhibitors
Authors: Bauer Kenneth A. , Hawkins David W. , Peters Paul C. , Petitou Maurice , Herbert Jean‐Marc , van Boeckel Constant A. A. , Meuleman Dirk G. 
Published: August 2010

ABSTRACTDespite currently available antithrombotic therapies, venous thromboembolism (VTE) remains a major cause of morbidity and mortality. Fondaparinux sodium (pentasaccharide), the first in a new class of antithrombotic agents developed for the prevention and treatment of VTE, inhibits thrombin generation by selectively inhibiting factor Xa. Fondaparinux exhibits complete bioavailability by the subcutaneous route and is rapidly absorbed, reaching its maximum concentration approximately 2 h post dosing. It has a terminal half‐life of 13 to 21 h, permitting once‐daily dosing. Fondaparinux's reproducible linear pharmacokinetic profile exhibits minimal intrasubject and intersubject variability, suggesting that individual dose adjustments will not be required for the vast majority of the population and that there will be no need for routine hemostatic monitoring. At therapeutic concentrations (<2 mg/L), fondaparinux exhibits >94% binding to its target protein, antithrombin. Within this same concentration range there is no specific binding by fondaparinux to plasma proteins commonly involved in drug binding, indicating a low potential for drug‐drug interactions by protein displacement. Unlike antithrombotic agents prepared from animal extracts (heparins), fondaparinux is chemically synthesized; this leads to batch‐to‐batch consistency and the absence of potential risk of contamination problems. In recently completed phase III clinical trials in VTE prevention in major orthopedic surgery, fondaparinux showed significant superiority over the low‐molecular‐weight heparin enoxaparin, providing an overall >50% (P < 0.001) reduction in VTE risk without increasing clinically important bleeding. Additional clinical data support its potential benefits in other venous and arterial thrombotic disorders. In view of these collective findings, fondaparinux is expected to play a major role in the prevention and treatment of venous and arterial thrombotic disease.